Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
DEC-C and Thioguanine for R/R AML
NCT06351306 · Columbia University · PHASE2 · withdrawn · last registry update 2025-03-24 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Difficultly enrolling” | Open Targets' class: insufficient enrollment | Registry record, Columbia University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IMPDH1 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-09-05Phase 3 first posted: Actinium Pharmaceuticals, 131I-apamistamab + Fludarabine (NCT07157514)
- 2025-06-13Results posted on the registry: Children's Oncology Group, Asparaginase + Asparaginase Erwinia chrysanthemi (NCT02521493)
- 2025-03-20Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Fludarabine + T Cell-Depleted Donor Lymphocyte Infusion (NCT02566304)
- 2024-07-10Also stopped (terminated): Loyola University, Cyclophosphamide + Tacrolimus (NCT03088709)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision